VanEck Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

VanEck Associates’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80,052	Closed	-$10.6M	–	1470
2025 Q1	$10.6M	Buy	+80,052	New	+$9.98M	0.01%	468

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

VanEck Associates's ITCI Position: Q2 2025 in Review

VanEck Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 80,052 shares — an estimated $10.6M sold.

VanEck Associates first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $10.6M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

VanEck Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
VanEck Associates sold 80,052 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $10.6M.
VanEck Associates first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
VanEck Associates's Intra-Cellular Therapies Inc. position peaked at $10.6M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on VanEck Associates's 13F filing for Q2 2025, filed 14 Aug 2025.